Results 1 to 10 of about 197,154 (267)

Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma

open access: yesTranslational Oncology, 2021
Purpose: To compare the efficacy and safety of anti-PD1 checkpoint inhibitor plus chemotherapy with anti-PD1 checkpoint inhibitor alone in recurrent and metastatic nasopharyngeal carcinoma (R/M NPC) progressing after first or subsequent-line therapy ...
Ting Jin   +4 more
doaj   +1 more source

Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis

open access: yesFrontiers in Cardiovascular Medicine, 2023
BackgroundImmune checkpoint inhibitor-related myocarditis is the deadliest complication of immunotherapy. However, the underlying pathophysiological mechanisms of its occurrence and development remain unclear. Due to the long-term lack of effective early
Xin Zhang   +8 more
doaj   +1 more source

The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity

open access: yesFrontiers in Medicine, 2022
Immune checkpoint inhibitors, medications that boost host immune response to tumor cells, are now at the forefront of anti-cancer therapy. While efficacious in the treatment of patients with advanced cancer, immune checkpoint inhibitors can lead to ...
Emily M. Moss   +2 more
doaj   +1 more source

Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study.

open access: yesPLoS ONE, 2021
BackgroundImmune checkpoint inhibitors, approved for the treatment of various types of cancer, are known to cause a unique spectrum of side effects, including acute kidney injury (AKI).
Marije S Koks   +8 more
doaj   +1 more source

Esophagitis dissecans superficialis with immune checkpoint inhibitor therapy

open access: yesCurrent Problems in Cancer: Case Reports, 2021
Immune checkpoint inhibitors represent an important advance in cancer treatment, but immune mediated adverse events associated with their use can be severe and life-threatening.
Alexis Coolidge   +3 more
doaj   +1 more source

A case series of morbid COPD exacerbations during immune checkpoint inhibitor therapy in cancer patients

open access: yesRespiratory Medicine Case Reports, 2021
Background: Immune checkpoint inhibitor therapy is rapidly becoming front line adjuvant or primary therapy in a number of solid cancer types. Since many of these cancers are a result of tobacco smoking, a large number of these patients will have ...
Viswam S. Nair   +2 more
doaj   +1 more source

Effectiveness of corticosteroids on immune checkpoint inhibitor-induced interstitial pneumonia among patients with a history of interstitial pneumonia: A case series

open access: yesSAGE Open Medical Case Reports, 2021
There are few reports on the effectiveness of corticosteroids for immune checkpoint inhibitor-induced interstitial pneumonia in patients with a history of interstitial pneumonia.
Takenori Ichimura   +3 more
doaj   +1 more source

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management

open access: yesKidney Medicine, 2021
Immune checkpoint inhibitors are now approved for more than 50 indications, and increasing numbers of patients with advanced cancer are receiving immunotherapy.
Harish Seethapathy   +2 more
doaj   +1 more source

Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model. [PDF]

open access: yesPLoS ONE, 2018
Oncolytic virus (OV) is a replication competent virus that selectively invades cancer cells; as these cells die under the viral burden, the released virus particles proceed to infect other cancer cells.
Avner Friedman, Xiulan Lai
doaj   +1 more source

Pembrolizumab related Guillain barre syndrome, a rare presentation in a patient with a history of lupus and bladder cancer

open access: yesJournal of Community Hospital Internal Medicine Perspectives, 2021
Immune checkpoint inhibitor-related neurotoxicity causing Guillain Barre Syndrome is relatively uncommon. We discussed an 80-year-old patient with known systemic lupus erythematosus who presented with lower extremity weakness, areflexia and then ...
Vikram Sangani   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy